1. Introduction {#sec1}
===============

With the largest population, the prevalence of diabetes in China is 11.6% of adults \[[@B1], [@B2]\]. It has been shown that all-age disability-adjusted life-years (DALYs) of diabetes were increased by 24.4% (95% CI: 22.7--26.2) from 1990 to 2016 according to the Global Burden of Disease Study \[[@B3]\]. The cost burden of diabetes increased about 100 times in 14 years \[[@B4], [@B5]\]. Type 2 diabetes mellitus (T2DM) occupied around 90%-95% of the disease.

Lifestyle intervention has been advocated to decrease the risk of T2DM in prediabetic subjects, which could reduce 3% absolute risk compared with no prevention \[[@B6]--[@B8]\]. The Da Qing Diabetes Prevention Study found that a 6-year lifestyle intervention program for those with impaired glucose tolerance (IGT) reduced the 17.3% cumulative incidence of diabetes (hazard ratio (HR): 0.55, 95% CI: 0.40-0.76) during the 23-year follow-up period \[[@B9]\]. Chinese diabetes society encouraged lifestyle intervention to decrease the risk of diabetes in general and high-risk population \[[@B10]\]. T2DM has become a leading health challenge in China. The cost-effectiveness of prevention strategies is emergent for informing health policy decision makers. Economic analysis in North America and Europe shows that lifestyle intervention is cost-effective relative to no prevention \[[@B11]\]. However, few evidences are currently available for Asian countries. Because the economic results from other countries may not be generalizable to the Chinese context, we sought to determine the anticipated health economic outcomes for lifestyle intervention in high-risk population and compare it to those with no prevention in the Chinese healthcare setting.

2. Methods {#sec2}
==========

2.1. Model Overview {#sec2.1}
-------------------

The economic analysis of primary prevention included the high-risk population of T2DM, who were initially assigned to lifestyle intervention or no prevention. The lifestyle intervention included the diet and exercise interventions. Based on the Da Qing Diabetes Prevention Study, the diet intervention was designed to produce weight loss in those who were overweight or obese and to reduce simple carbohydrate and alcohol intake in people of normal weight. The exercise intervention was designed to increase the leisure time spent doing physical activity \[[@B9]\].

The analysis was carried out by using a mathematical model, which could annually track the T2DM progression from prediabetes ([Figure 1](#fig1){ref-type="fig"}). Once the patients developed T2DM, the disease course would be projected by using the Chinese Outcomes Model for T2DM (COMT) \[[@B8], [@B12], [@B13]\]. This validated diabetes policy analysis model would track simultaneously several critical diabetic macro- and microvascular complications for one hypothetical T2DM patient, including myocardial infarction (MI), congestive heart failure (CHF), cardiovascular disease (CVD), stroke, blindness, end-stage renal disease (ESRD), clinical neuropathy, foot ulcer, and minor and major amputation. One patient could incur different complications at the same time. The all-cause mortality would be adjusted based on the treatment effect and disease status. Each diabetic complication is an independent submodel that was integrated with the COMT model. The transition probabilities of the model were estimated according to the latest Risk Equations for Complications of Type 2 Diabetes (RECODe) \[[@B14]\], which is adjusted validated based on the Chinese patient characteristics of T2DM. The details about the model development and validation could be found in our previous report \[[@B12]\]. During the model simulation, interconnectivity and interaction among submodels of individual complication were permitted to allow the complication risks to be updated by using tracker parameters. The clinical and demographic characteristics of the hypothetical cohorts with T2DM were used for determining the annual disease progression: sex, age, smoking status, systolic blood pressure (SBP), glycated haemoglobin (HbA1c), total and high-density lipoprotein (HDL) cholesterol levels, serum creatinine, urine albumin : creatinine ratio, history of cardiovascular disease, and use of antihypertensive, anticoagulant medications, statin, and oral diabetes medication. During the simulation, risk parameters might be updated based on the treatment transition, thereby resulting in the likelihood of complication incidence. HbA1c, SBP, and cholesterol would worsen over time. More details about the model process could be found in our previous work \[[@B12]\]. The design of the model was the same for lifestyle intervention and no prevention strategies, with only risks of developing complications adjusted by the use of the different intervention.

Lifetime health such as complication probabilities life-year (LY) and quality-adjusted life-year (QALY) and costs would be processed in the current analysis. Costs and QALY were annually discounted at 5%, according to data released by the Chinese health economic recommendation \[[@B15]\]. Cost-effectiveness was defined if the incremental cost-effectiveness ratios (ICERs) were less than the per capita gross domestic product (GDP) of China in 2019 (\$10,276) \[[@B15]\].

2.2. Patient Profile and Disease Progression {#sec2.2}
--------------------------------------------

Based on the Chinese practice, individuals with high risk for diabetes were screened to confirm the glycemic state by oral glucose tolerance test \[[@B16]\]. The population characteristic profile was assumed to be similar to the Da Qing Diabetes Prevention Study, which enrolled 577 Chinese adults with confirmed IGT whose baseline characteristics were shown as follows: 45 years old, 54% of male, BMI 25.8 kg/m^2^, SBP 132.9 mmHg, DBP 87.6 mmHg, FPG 5.57 mmol/L, 2hPG 9.0 mmol/L, and current smoker 41.2% \[[@B9]\]. This trial showed that the incidence of diabetes was 72.6% (68.4-76.8) in the intervention group versus 89.9% in the control group (84.9-94.9; HR 0.55, 95% CI 0.40-0.76; *p* = 0.001) \[[@B9]\]. The Kaplan-Meier curves of developing diabetes in a 23-year follow-up were fitted by using the Weibull survival function *S* (*t*) = exp(--*αt*^*β*^), whose parameters are shown in [Table 1](#tab1){ref-type="table"}. Patients with T2DM would incur the macro- and microvascular disease, whose risks in COMT model were estimated by using the adjusted Risk Equations for Complications of Type 2 Diabetes (RECODe) \[[@B14]\]. For those without diabetes, the risks of the macro- and microvascular disease were estimated by multiplying the absolute risks in diabetic patients and the relative risks of subjects without diabetes versus diabetic patients, which were derived from the published literature \[[@B17]--[@B24]\]. The natural mortality rates were based on the 2009 Chinese life tables reported by the World Health Organization (WHO) \[[@B25]\].

2.3. Costs and Utility {#sec2.3}
----------------------

The current study was presented from the point of the Chinese healthcare provider. Therefore, medical costs were the focus in the model ([Table 1](#tab1){ref-type="table"}). All data were shown in the 2019 US dollar (1 US dollar = CNY ¥ 6.9). Because the lifestyle intervention for high-risk population and diabetic population was comparable \[[@B9], [@B16]\], we assumed that the cost related to lifestyle intervention was similar with an economic study in China \[[@B26]\], which reported that the annual cost of diabetic education was \$134.0 per patient. This fee would be used for paying the works of practice nurses, who would educate and prescribe a lifestyle prescription for patient. The annual costs of medicine and glucose testing strips were originated from a large scale population-based study \[[@B27]\]. The costs of inpatient and outpatient visits due to vascular complications were extracted directly from publications \[[@B4], [@B28]--[@B32]\]. The expense of severe hypoglycemic events was derived from a Chinese costing study, which included 275 patients who incurred hypoglycemic episode \[[@B33]\]. The target population has been confirmed with prediabetes, so the cost related to an oral glucose tolerance test was not included in this analysis.

Utility scores were collected from a recent study. It involved 289 T2DM patients in China. The utility scores of neuropathy, heart disease, and cerebrovascular disease were analyzed by using EQ-5D-5L \[[@B34]\].

2.4. Sensitivity Analysis {#sec2.4}
-------------------------

One-way and probabilistic sensitivity analyses (PSA) were used to analyze the potential drivers of economic outcomes. The range of the ICERs between low and high values was shown in [Table 1](#tab1){ref-type="table"}. Ranges from 75% to 125% of base case values were assumed when there was no available data. In PSA with the second-order Monte-Carlo simulations (1000 iterations), all model variables were attached by probability distributions. The probability, proportions, and utility scores followed beta distribution, a triangle distribution was modeling for cost, and normal distribution was for hazard ratio and patient characteristics. If there was no reported data, we assumed 25% of the base case value to be the standard error. Cost-effectiveness acceptability curve (CEAC) was generated based on the results of PSA.

3. Results {#sec3}
==========

3.1. Base Case Analysis {#sec3.1}
-----------------------

In comparison with no prevention, the lifestyle intervention reduced the 9.53% cumulative probabilities of diabetes, which resulted in mean additional benefits in life expectancy and QALY of 0.82 years and 0.52 QALYs, respectively, at saved total mean costs of \$700 over a lifetime period ([Table 2](#tab2){ref-type="table"}). The ICER between lifestyle intervention and no intervention was \$ -1339 per QALY gained (dominant strategy).

3.2. Sensitivity Analysis {#sec3.2}
-------------------------

The model was more sensitive to the cost of the lifestyle intervention and the hazard ratio of developing diabetes between lifestyle intervention and no intervention because they were found to have a substantial impact on ICER. The remainder sensitive variables, such as the cost and utility of managing diabetes and its complications, had a medium or small impact ([Figure 2](#fig2){ref-type="fig"}). However, none of the adjustments of parameters could lead the ICERs to be higher than \$10,276/QALY.

In the probabilistic sensitivity analyses ([Figure 3](#fig3){ref-type="fig"}), the cost per additional QALY gained for lifestyle intervention over no prevention was \$ -1578 (95% CI: \$ -2858 to \$ -821). At an acceptable ICER of \$10,276 (GDP per capita of China in 2019), over 95% probabilities of cost-effectiveness were produced by lifestyle interventions according to the acceptability curve ([Figure 4](#fig4){ref-type="fig"}).

4. Discussion {#sec4}
=============

Reports of the health benefits of lifestyle intervention in clinical trials excite both endocrinologists and prediabetic subjects. However, lifestyle intervention accompanies with a considerable increase in healthcare costs compared with no prevention, which is of concern to payers. The need for the precise economic evaluation of implementing lifestyle intervention in the Chinese context is becoming urgent. It is the first economic evaluation that estimated, in Chinese subjects with prediabetes, the initiation of lifestyle intervention was associated with improvements in length and quality of life and saving money by preventing or delaying T2DM. Sensitivity analysis showed that economic outcomes were not sensitive to the adjustments of the model inputs and assumptions and kept the life intervention strategy cost-effective. This finding is emphasized by the involvement of the COMT model, which is a well-established model for surrogate endpoints such as blood glucose, blood pressure, and lipid profiles in the Chinese population. Our analysis indicated that lifestyle intervention is worth implementing in the Chinese healthcare system as it is considered to be very cost-saving. This study presents a key step in the Chinese diabetes prevention policy: whether to aim interventions at those with the most attractive ICERs (\<per capita GDP).

Our findings are comparable with those previously published economic evaluations. One systematic review summarized that those cost evaluations of lifestyle interventions in high-risk diabetic subjects are cost-effective \[[@B35]\]. The ICERs of lifestyle intervention programs against no prevention varied from cost-saving to \$175,754/QALY with a median value of £9,793/QALY. However, there are few studies in low-income and middle-income regions. Literature reveals that lifestyle intervention for diabetes was cost-effective among high-risk Indian \[[@B36]\]. One Chinese study also demonstrated that appropriate lifestyle interventions for those with IGT are cost-saving in China \[[@B37]\]. However, this study reported by Liu and colleagues did not separately report the economic outcome of lifestyle intervention in high-risk population due to their study goal. Differences in study design, model structure, assumptions, and inputs contribute to the variation of ICERs in these economic reports.

This study has some limitations. Firstly, lifestyle interventions led to notable improvements in the risk profiles of cardiovascular disease in normal adults, which might further decrease CVD risk \[[@B38]\]. By using a conservative approach to measure the health outcomes of lifestyle modification, we did not consider the health benefits in the population who did not develop diabetes and other types of disease (e.g., obesity-related cancers or dementia), which might underestimate the economic outcomes of lifestyle intervention. Secondly, due to the absence of solid evidence in the Eastern population, the current analysis did not include metformin as a competing alternative for preventing diabetes, which also showed cost-effectiveness in other regions \[[@B35]\]. Thirdly, some of the clinical data obtained from literature might not be related to Chinese data. However, since the sensitivity analysis is robust, these may be taken into account. Lastly, since the analysis is based on the Da Qing Diabetes Prevention Study that only enrolled subjects with IGT, the economic outcome may be affected if prediabetic subjects differ significantly from it, such as the subjects with impaired fasting glucose, whose aetiologies seem to differ from IGT \[[@B39]\]. The sensitivity analyses showed that ICER is comparatively sensitive to the effectiveness of lifestyle interventions, although cost-effective might be plausible for Chinese given our reading of the current study. Future research should focus on establishing individualized preventive strategies based on the differently prediabetic states \[[@B40]\]. Nevertheless, as the results of this analysis address the common health issues of diabetes in China, we believe these results can be an important reference point for Chinese policymakers.

In summary, according to the analysis in our study, lifestyle intervention is a cost-effective alternative for prediabetic subjects and worth implementing in the Chinese healthcare system. The preventive program needs to be tailored in order to further optimize the allocation of health resources in future research.
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###### 

Key model inputs.

  Parameters                                                         Expected values             Ranges              Source
  ------------------------------------------------------------------ --------------------------- ------------------- ---------------------------
  Clinical data                                                                                                      
   Weibull function parameters                                                                                       
    No prevention                                                    *α* = 0.177, *β* = 0.8551   NA                  \[[@B9]\]
    Life interventions                                               *α* = 0.0749, *β* = 0.96    NA                  \[[@B9]\]
   RR of diabetes of life interventions vs. no prevention            0.55                        0.4-0.76            \[[@B9]\]
   RR of MI of T2DM vs. no diabetes                                  2                           1.83-2.19           \[[@B17]\]
   RR of stroke of T2DM vs. no diabetes                              2.27                        1.95-2.65           \[[@B17]\]
   RR of CVD death of T2DM vs. no diabetes                           2.38                        1.45-3.92           \[[@B17]\]
   RR of CHF of T2DM vs. no diabetes                                 2.5                         2.3-2.7             \[[@B18], [@B19]\]
   RR of blindness of T2DM vs. no diabetes                           1.43                        1.04-2.32           \[[@B21], [@B22]\]
   RR of clinical neuropathy of T2DM vs. no diabetes                 4.60                        3.18-6.02           \[[@B23], [@B24]\]
   RR of chronic kidney disease of T2DM vs. no diabetes              2.38                        1.45-3.92           \[[@B20]\]
  Costs (US \$)^\#^                                                                                                  
   Life interventions                                                134.0                       43.8-611.6          \[[@B26]\]
   Antidiabetic therapy per day (disease duration ≤ 2 years)         0.5                         0.1-1.2             \[[@B27]\]
   Antidiabetic therapy per day (3 \< disease duration ≤ 5 years)    0.8                         0.1-1.6             \[[@B27]\]
   Antidiabetic therapy per day (6 ≤ disease duration \< 10 years)   1.2                         0.3-2.3             \[[@B27]\]
   Antidiabetic therapy per day (disease duration≥10 years)          1.8                         0.7-3               \[[@B27]\]
   MI hospitalization per event                                      6955.0                      6128-7782           \[[@B4], [@B28]--[@B30]\]
   Care after MI per year                                            429.0                       271.9-586.1         \[[@B4], [@B28]--[@B30]\]
   Stroke hospitalization per event                                  2708.6                      2058-4463.6         \[[@B4], [@B28]--[@B30]\]
   Care after stroke per year                                        477.5                       420.1-780           \[[@B4], [@B28]--[@B30]\]
   CHF per year                                                      1420.3                      1181.9-2479.7       \[[@B4], [@B28]--[@B30]\]
   ESRD per year                                                     13,003.0                    12,391.3-13,724.6   \[[@B31]\]
   Blindness per year                                                1546.8                      1347.5-1746         \[[@B4], [@B28]--[@B30]\]
   Clinical neuropathy per month                                     57.4                        24.7-95.5           \[[@B32]\]
   Uncomplicated DFU per event                                       71.7                        0-213               \[[@B32]\]
   Complicated DFU per event                                         2160.3                      1157.2-2713.8       \[[@B32]\]
   Minor amputation per event                                        3124.6                      2039.7-4746.8       \[[@B32]\]
   Major amputation per event                                        4728.3                      2808.3-7289.6       \[[@B32]\]
   Care after major amputation per month                             318.5                       0-565.9             \[[@B32]\]
   Severe hypoglycemia per event                                     534.4                       400.8-667.9         \[[@B33]\]
  Utility values                                                                                                     
   T2DM without complications                                        0.876                       0.736-1             \[[@B34]\]
  Utility decrements                                                                                                 
   MI hospitalization for one month                                  1.000                       0.236-1             \[[@B34]\]
   MI after discharge                                                0.236                       0.026-0.446         \[[@B34]\]
   Stroke hospitalization for one month                              1.000                       0.326-1             \[[@B34]\]
   Stroke after discharge                                            0.326                       0.036-0.616         \[[@B34]\]
   CHF                                                               0.236                       0.026-0.446         \[[@B34]\]
   ESRD                                                              0.400                       0.19-0.61           \[[@B4], [@B28]--[@B32]\]
   Blindness                                                         0.157                       0.007-0.307         \[[@B4], [@B28]--[@B32]\]
   Clinical neuropathy                                               0.185                       0.015-0.355         \[[@B34]\]
   Uncomplicated DFU                                                 0.250                       0.213-0.287         \[[@B4], [@B28]--[@B32]\]
   Complicated DFU                                                   0.300                       0.165-0.435         \[[@B4], [@B28]--[@B32]\]
   Minor amputation                                                  0.320                       0.204-0.436         \[[@B4], [@B28]--[@B32]\]
   Major amputation                                                  0.380                       0.264-0.496         \[[@B4], [@B28]--[@B32]\]

Abbreviations: NA: not applicable; RR: relative risk; T2DM: type 2 diabetes mellitus; DFU: diabetic foot ulcers; MI: myocardial infarction; CHF: congestive heart failure; CVD: cardiovascular disease; ESRD: end-stage renal disease. ^\#^All cost data were shown in the 2019 US dollar (1 US dollar = CNY ¥ 6.9).

###### 

Base case results for lifestyle interventions compared to no prevention.

  Outcomes                                    No prevention   Lifestyle interventions   Difference^∗^
  ------------------------------------------- --------------- ------------------------- ---------------
  Cumulative probabilities of diabetes        93.57%          84.04%                    -9.53%
  Cumulative probabilities of complications                                             
   MI                                         10.56%          9.93%                     -0.63%
   Stroke                                     24.17%          22.62%                    -1.55%
   CHF                                        14.89%          13.71%                    -1.18%
   ESRD                                       4.61%           4.22%                     -0.39%
   Blindness                                  5.79%           5.66%                     -0.13%
   Clinical neuropathy                        21.28%          20.25%                    -1.03%
   Minor amputation                           12.21%          10.55%                    -1.66%
   Major amputation                           9.22%           7.94%                     -1.28%
  Total QALY                                  13.03           13.55                     0.52
  Total LY                                    27.87           28.68                     0.82
  Total cost (US \$)^\#^                      11,390          10,689                    -700
  ICER (US \$/QALY)                           NA              Dominant                  

^∗^Compared with the control strategy (no prevention). ^\#^All cost data were shown in the 2019 US dollar (1 US dollar = CNY ¥ 6.9).
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